Testing a new nasal spray for children with nasal allergies
Treatments studied
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new nasal spray (DEP114) to see if it helps control moderate to severe allergic rhinitis symptoms in children. It compares the spray to a standard steroid nasal spray.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 11 years old.
- They must have moderate to severe persistent nasal allergies (allergic rhinitis) that bother them most days.
- They must have a positive skin or blood test for common airborne allergens (like pollen, dust mites, or pet dander).
- They cannot have used any steroid medication (like prednisone) or allergy medicines (like antihistamines or decongestants) by mouth, injection, or spray in the last week.
- They cannot have severe or uncontrolled asthma, or other serious health issues.
- They cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether PL-14, a new nasal spray, works better than saline spray at relieving seasonal allergy symptoms like sneezing, itching, and congestion. If it works well and is safe, it could offer patients a new way to manage allergies during pollen season.
This trial tests whether a seawater nasal spray can relieve nasal congestion, runny nose, and other sinus symptoms in people with colds, allergies, or after nose surgery. You will use the spray as directed and answer online questionnaires for up to 3 months.
This study tests a new nasal spray (ALDP001) in adults with seasonal allergies to ragweed. It aims to find the best dose and how often to use it.
This trial tests a new nasal spray for people with perennial (year-round) allergic rhinitis. It aims to see if the medicine works well and is safe compared to other treatments.
This trial tests Dymista, a nasal spray combining an antihistamine and steroid, in teenagers aged 12–17 with moderate-to-severe allergic rhinitis (nasal allergies that disrupt sleep, school, or daily life). The study will see how well it works and if it's safe for this age group.
This study tests a new nasal spray (PG-011) for adults with moderate-to-severe seasonal allergies (hay fever). It compares the spray to a placebo to see if it reduces nasal symptoms like stuffiness, sneezing, and runny nose.
Hear when a new Allergic Rhinitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.